Balchem (BCPC) Q1 2025 earnings summary

Executive summary

• Achieved record Q1 net sales of $251 million, up 4.5% year-over-year, with growth in all three business segments and margin expansion driven by favorable portfolio mix and volume leverage.

• Net earnings rose 27.8% to $37.1 million, with adjusted EBITDA reaching $66.3 million, up 8.9% from prior year.

• All segments contributed to profit growth, supported by new product launches, innovation, and healthy market conditions.

• The company maintains a strong margin profile, efficient cash flow conversion, and a solid balance sheet.

• Launched new product brand sites and released the 2024 Sustainability Report, underscoring commitment to innovation and stewardship.

Financial highlights

• Gross margin dollars grew 8.2% to $88.2 million, with gross margin percent at 35.2%, up 120 basis points.

• GAAP EPS was $1.13, up from $0.89; adjusted EPS was $1.22, up from $1.03.

• Free cash flow was $31 million; cash flows from operations totaled $36.5 million.

• Net interest expense declined to $2.9 million from $5.4 million due to lower borrowings.

• Annual dividend reached $0.87/share in 2024, with a 11.2% CAGR over the last decade.

Outlook and guidance

• Management remains confident in long-term growth, citing strong market positions, resilient business model, and continued investment in innovation and expansion.

• Expectation of continued growth in Human Nutrition and Health and Animal Nutrition and Health segments.

• Effective tax rate for the full year expected to be in the 22%-22.5% range; Q1 2025 adjusted effective tax rate was 23.9%.

• Foreign currency appreciation could provide a $10-$15 million annualized revenue tailwind if rates remain favorable.

• Management expects strong cash flow to fund working capital, capital investments, and potential acquisitions.